RxDoctor Payments Data

Alexandria Aliotti

Physician Assistant · Salinas, CANPI 1689258659

Payments from drug & device makers

$4,163in general payments, 2019–2025

Across 180 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$454
  • Johnson & Johnson$430
  • Philips North America LLC$412
  • Merck$359
  • AstraZeneca$281
  • Novo Nordisk$280
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,162100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,163 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$139,937
Medicare patients
651
Services billed
1,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$239,705
JardianceEmpagliflozin81$81,499
XareltoRivaroxaban40$53,006
Repatha SureclickEvolocumab45$38,426
FarxigaDapagliflozin Propanediol33$20,588
BrilintaTicagrelor17$19,718
EntrestoSacubitril/Valsartan19$19,336
Ezetimibe121$5,727
Metoprolol Succinate317$4,446
Atorvastatin Calcium314$3,206
Rosuvastatin Calcium145$2,903
Amiodarone Hcl49$2,202
Propafenone Hcl41$1,832
Nitroglycerin63$1,792
Losartan Potassium176$1,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$262$239,705226 claims
Boehringer IngelheimJardiance$213$81,49981 claims
Johnson & JohnsonXarelto$430$53,00640 claims
AstraZenecaFarxiga, Brilinta$281$40,30550 claims
NovartisEntresto$454$19,33619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →